American Medical AssociationUptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy

In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.

American Medical AssociationAssociation Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer

In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials.

American Society of Clinical OncologyTROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients w. Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to […]

American Society of Clinical OncologyPalbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

The Journal of Clinical Oncology presents a Rapid Communications summary of the PENELOPE-B trial, a double-blind, placebo‐controlled, phase III study in women with HR+, HER2- primary breast cancer without a pathological complete response after taxane‐containing NACT and at high risk of relapse. With about one-third of women relapsing, palbociclib – a cyclin-dependent kinase 4 and […]

HMP CommunicationsAnti–PD-L1 Therapy Not Recommended for Patients w. NSCLC, Active Brain Metastases

Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic […]

Millennium Medical PublishingChoosing Between Novel Agents and Chemoimmunotherapy in CLL

From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when […]